We are live on !
Find out more
GTC
Ghost Tree Capital Portfolio holdings
AUM
$331M
Turnover
44%
1-Year Est. Return
70.11%
This Fund
S&P 500
This Quarter Est. Return
+22.21%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,043.31%
AUM
$303M
AUM Growth
-$35.4M
(-10%)
Cap. Flow
-$5.7M
Cap. Flow % of AUM
Cap. Flow %
-1.88%
Top 10 Holdings %
Top 10 Hldgs %
52.11%
Holding
73
New
15
Increased
24
Reduced
14
Closed
16
Avg Time Held
Equity + Options
0.8
years
Top 10 Avg Time Held
Equity + Options
0.3
years
Top 20 Avg Time Held
Equity + Options
0.7
years
Avg Time Held Equity only
0.8
years
Top 10 Avg Time Held Equity only
0.4
years
Top 20 Avg Time Held Equity only
0.8
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Revance Therapeutics
RVNC
|
+$8.57M |
| 2 |
Madrigal Pharmaceuticals
MDGL
|
+$6.77M |
| 3 |
BeOne Medicines
ONC
|
+$5.18M |
| 4 |
Akero Therapeutics
AKRO
|
+$3.9M |
| 5 |
Vir Biotechnology
VIR
|
+$3.77M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Axsome Therapeutics
AXSM
|
+$8.48M |
| 2 |
CTIC
CTI BioPharma
CTIC
|
+$8.4M |
| 3 |
Pfizer
PFE
|
+$8.16M |
| 4 |
Johnson & Johnson
JNJ
|
+$7.75M |
| 5 |
TG Therapeutics
TGTX
|
+$7.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 91.47% |
| 2 | Miscellaneous | 8.53% |
Similar funds
AFS
E
Ghost Tree Capital's Q2 2023 Portfolio in Review
As of Q2 2023, Ghost Tree Capital held 73 positions worth $303M, down 10% from $338M the previous quarter. Its ten largest holdings account for 52% of the portfolio.
Ghost Tree Capital's Q2 2023 filing shows 15 new, 24 increased, 14 reduced and 16 closed positions. Its largest new stake was BeOne Medicines: 22,500 shares worth $4.01M. The largest sale was Axsome Therapeutics, an estimated $8.48M.
By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 78% a quarter earlier, followed by Miscellaneous.
- Ghost Tree Capital's largest Q2 2023 buy was BeOne Medicines: 22,500 shares worth $4.01M.
- Ghost Tree Capital added most to Revance Therapeutics in Q2 2023, an estimated $8.57M increase.
- Ghost Tree Capital's biggest Q2 2023 reduction was Axsome Therapeutics, cutting an estimated $8.48M.
- Ghost Tree Capital fully exited CTI BioPharma in Q2 2023, selling an estimated $8.4M.
- Ghost Tree Capital's ten largest holdings make up 52% of its $303M portfolio in Q2 2023.
- Ghost Tree Capital opened 15 new positions and closed 16 in Q2 2023.
- Ghost Tree Capital's portfolio value fell 10% quarter-over-quarter to $303M.
Based on Ghost Tree Capital's 13F filing for Q2 2023, filed 14 Aug 2023.